Intas launches rituximab biosimilar, Mabtas in India

April 22, 2013 10:08 AM

Intas Pharmaceuticals, has recently declared that, they began to sell Mabtas, biosimilar rituximab in the Indian market. 

The company’s subsidary Intas Bio-Pharma was already selling some biosimilars, including G-CSF, Pegylated G-CSF and also erythropoietin with their own brands. Now, with a recent update, they declared that, a biosimilar version of Roche/Genentech’s Rituxan/Mabthera is being marketed in India.

“With a view to make Non-Hodgkin’s Lymphoma (NHL) treatment cost-effective, Intas Pharmaceuticals Limited has successfully launched “Mabtas” in India.
Mabtas is a biosimilar version of rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. Such diseases include many forms of lymphoma, leukemia, and transplant rejection, autoimmune disorders such as Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis.
Mabtas may be used alone or in combination with other chemotherapy medicines to treat Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).” the company said in their news update.

We have to note once again that, this product is not developed in accordance with global biosimilar guidelines and like Reditux, which was developed by Dr.Reddy’s, it is launched in India first.


Source: Intas Pharmaceuticals

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!